



TB WORKS IN PROGRESS SERIES



CURED, BUT NOT HEALED: EPIGENETIC TRADE-OFFS, IMMUNE AGING, AND THE NEED FOR ENDOTYPE-SPECIFIC THERAPIES IN TB

Andrew DiNardo, MD, PhD

Dr. Andrew DiNardo is a physician-scientist and Associate Professor at Baylor College of Medicine. He studies the metabolic and epigenetic regulation of host immunity during and after infections. This work has identified that tuberculosis induces epigenetic perturbations that persist despite successful antibiotics. The studies have demonstrated that TB survivors have 12 years of premature epigenetic aging, with the post-TB DNA methylation changes being driven by TCA metabolites. Building off work in his PhD studies at Radboud University, he is focused on translating endotype classifiers into actionable, host directed therapies.



Friday October 16, 2026



9 - 10 am



RSPH CNR 3001 & Zoom

<https://zoom.us/j/91959206915>

